According to FutureWise analysis the market for acute migraine treatment in 2023 is US$ 2.52 billion, and is expected to reach US$ 3.76 billion by 2031 at a CAGR of 5.10%.
Migraine is one of the most recurring neurological conditions that commonly causes painful headache attacks that occur with other symptoms, such as sensitivity to light, sound, smell, or touch. Some individuals may experience a pre-headache warning symptom known as an aura, including visual aberrations such as light flashes or blind spots. It may also involve other sensations like tingling on one side of the face or in an arm or leg and speech difficulties. It may last at least four hours or even days. Currently, for the acute medicine of migraine attacks, Acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), triptans (serotonin 5HT1B/1D receptor agonists), and combination analgesics are recommended for effectiveness in the treatment of migraines.
Analgesics is the first-line drug in the treatment of mild or moderate migraine attacks. Paracetamol and nonsteroid anti-inflammatory drugs (NSAIDs) are a significant group of analgesics capable of producing analgesic and anti-inflammatory effects. Anti-inflammatory analgesics reduce inflammation, and opioid analgesics change how the brain perceives despair. Many types of analgesics are available, from pills and liquids to gels and patches you apply to your body. Some analgesics can be purchased over the counter, and others are available by prescription only. The mechanism of action of these drugs is on the central nervous system. They are apt to inhibit cyclooxygenases and thereby decrease the production of prostaglandin.
FutureWise Market Research has published a report that provides an insightful analysis acute migraine treatment market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, Acute Migraine Treatment Market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.